QIAGEN N.V.

QGEN Healthcare Diagnostics & Research

QIAGEN N.V.’s revenue for fiscal 2025 (year ended December 2025) was $2.1 billion, up 5.65% from fiscal 2024. In the quarter to June 2026, revenue was flat, EPS grew 7.94%, free cash flow grew 30.5% and total debt rose 13.8%, each against the same quarter a year earlier.

46.13 0.04 −0.09%
Market cap
$9.5B
P/E
23.6×
Fwd P/E
17.5×
Dividend yield
0.76%
F-score
8/9
Altman Z
3.81
Beneish M
−2.60
Dividend safety
66/100
Jun '26 Mar '26 Dec '25 Sep '25 Older periods
ROE
11.93% 11.93% 11.57% 11.29%

+8 more TTM periods

Piotroski F-Score
7 7 8 7
ROA
6.99% 7.10% 7.10% 6.32%
ROIC
6.62% 6.27% 6.72% 7.43%
Return on Tangible Assets
20.48% 20.35% 17.65% 16.51%
Average Days of Receivables
67.75 68.97 70.31 66.20
Free Cash Flow per Share
2.14 1.95 2.06 2.29
Free Cash Flow
440.60 403.87 447.20 472.50
Capital Expenditures
(213.87) (211.34) (207.13) (185.20)
Other line items
Cash ROIC
7.60% 7.18% 6.85% 6.33%
Accounts Receivable Turnover
5.42 5.69 5.56 5.74
Accounts Payable Turnover
9.84 10.79 10.14 9.93
Inventory Turnover
2.63 2.70 2.72 2.49
Average Days of Payables
36.36 35.79 33.55 35.76
Days of Inventory on Hand
143.16 141.53 139.39 138.79
Tax Rate
(0.11) (0.12) (0.13) (0.20)
Research and Development Expense of Revenue
9.27% 9.15% 8.97% 9.12%
Selling, General and Administrative Expense of Revenue
27.91% 28.02% 27.93% 27.60%
Share Based Compensation of Revenue
2.09% 2.27% 2.41% 2.16%
Interest Coverage
11.30 11.75 14.01 14.17
Operating CF/Net income
1.60 1.53 1.54 1.62
Depreciation/Fixed assets
0.22 0.22 0.21 0.22
Capex/Depreciation
(1.04) (1.03) (1.05) (0.95)
Revenue per Share
10.18 10.14 9.62 10.05
Operating CF per Share
3.17 2.97 3.01 3.19
Capex per Share
(1.04) (1.02) (0.95) (0.90)
Capex to Sales
0.10 0.10 0.10 0.09

Fold the line items

Columns are period end dates